HOME >> BIOLOGY >> NEWS
Large community-based clinical trial in older cancer patients suggests benefits of Neulasta

ORLANDO, Fla., (May 15, 2005) Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that an initial report from a study of 701 older cancer patients with solid tumors demonstrates Neulasta (pegfilgrastim) administered beginning in the first cycle of myelosuppressive chemotherapy resulted in reductions in febrile neutropenia (low white blood cell count with fever) and related complications, compared to those who received Neulasta in later chemotherapy cycles after developing a low white blood cell count. The study results were presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). [Abstract #8111]

"Despite the fact that more than 60 percent of cancers are diagnosed in patients 65 years or older, these patients may be under-represented in clinical trials and may also be under-treated, partly due to concern over treatment side effects, such as neutropenia, which may lead to hospitalizations and dose delays or reductions," said Lodovico Balducci, M.D., professor of medicine and oncology, University of South Florida College of Medicine, and division chief of the Senior Adult Oncology Program at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla. "This is the largest, prospective study of older patients demonstrating the feasibility of community-based clinical trials in these patients, as well as the ability of these patients to undergo myelosuppressive chemotherapy."

The study showed a decrease of approximately 60 percent in the incidence of febrile neutropenia across all cycles (4 percent versus 10 percent, respectively), as well as a 50 percent decrease in chemotherapy dose reductions (7 percent versus 14 percent) in patients receiving Neulasta beginning in the first cycle of chemotherapy compared to those who received Neulasta in later cycles. Febrile neutropenia, the primary endpoint of the study, was defined as an absolute neutrophil count (ANC) < 1 x 109/L and
'"/>

Contact: Kristen Davis
805-447-4587
Porter Novelli
16-May-2005


Page: 1 2

Related biology news :

1. Largest synthetic gene ever built offers insights into anti-malarial drug resistance
2. Largest ever study of genetics of common diseases published today
3. Largest physics meeting of the year, in Denver
4. Largest-ever search for autism genes reveals new clues
5. Largest genomic search finds genes that may contribute to autism
6. Large size crucial for Amazon forest reserves
7. Large European survey reveals critical gaps in breast cancer patient education and communication
8. Large dinosaurs were extremely hot in their day, UF study finds
9. Large-scale genomics project will hunt genes behind common childhood diseases
10. Large family study pinpoints genetic linkage in drug addiction
11. Largest study of human interactome reveals a novel way

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics ... recognition and multiple awards for not only the products and treatments developed, but ... and Vivace® Microneedle RF. All the brands built by ABM have received several ...
(Date:7/2/2020)... Md. (PRWEB) , ... July ... ... Molecular Biology Systems, B.V. (MBS) has announced a publication detailing the use ... one-step reverse transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a ... most common and aggressive adult brain cancer—announced today the appointments of its first ... charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows are ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... , ... August 13, 2020 , ... True Terpenes ... creation of its Scientific Advisory Board (SAB) to research the medical potential of terpenes ... be enhanced when combined with terpenes. The board is focused on expanding the recently ...
(Date:8/12/2020)... ... 11, 2020 , ... The FSHD Society announced today that ... Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on funding of ... academic research centers in the United States and Europe with expertise in FSHD ...
(Date:8/12/2020)... ... August 12, 2020 , ... Inc. magazine ... global leader in FDA compliance consulting has been named on its annual Inc. ... list represents a unique look at the most successful companies within the American ...
(Date:8/3/2020)... PHILADELPHIA (PRWEB) , ... August 03, 2020 , ... ... data collection, today announced Jim Corrigan, President and CEO has been named one ... a broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on ...
Breaking Biology Technology:
Cached News: